D.E. Shaw & Co’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28M Buy
200,919
+8,214
+4% +$1.15M 0.02% 945
2025
Q4
$23.7M Sell
192,705
-221,057
-53% -$26.9M 0.01% 1148
2025
Q3
$45.9M Sell
413,762
-286,466
-41% -$32.6M 0.03% 700
2025
Q2
$77.6M Buy
700,228
+246,472
+54% +$26.2M 0.06% 402
2025
Q1
$50.8M Sell
453,756
-558,706
-55% -$57.6M 0.05% 475
2024
Q4
$93.5M Buy
1,012,462
+271,261
+37% +$24.4M 0.07% 344
2024
Q3
$62.1M Sell
741,201
-2,597,051
-78% -$198M 0.05% 429
2024
Q2
$229M Buy
3,338,252
+2,203,342
+194% +$147M 0.21% 97
2024
Q1
$83.1M Buy
1,134,910
+178,269
+19% +$13.7M 0.07% 314
2023
Q4
$77.5M Sell
956,641
-1,373,449
-59% -$107M 0.07% 339
2023
Q3
$175M Buy
2,330,090
+279,963
+14% +$21.5M 0.18% 114
2023
Q2
$158M Buy
2,050,127
+212,149
+12% +$16.9M 0.16% 136
2023
Q1
$152M Sell
1,837,978
-178,062
-9% -$14.7M 0.16% 121
2022
Q4
$173M Buy
2,016,040
+1,563,996
+346% +$124M 0.19% 94
2022
Q3
$27.9M Sell
452,044
-1,319,616
-74% -$83.2M 0.03% 666
2022
Q2
$110M Sell
1,771,660
-3,373,926
-66% -$209M 0.13% 164
2022
Q1
$306M Buy
5,145,586
+4,454,256
+644% +$285M 0.29% 43
2021
Q4
$50.2M Buy
+691,330
New +$47.6M 0.04% 545
2021
Q2
Sell
-609,167
Closed -$40.7M 4841
2021
Q1
$39.4M Buy
609,167
+238,201
+64% +$15.4M 0.04% 591
2020
Q4
$21.6M Buy
370,966
+45,059
+14% +$2.72M 0.02% 923
2020
Q3
$20.6M Sell
325,907
-104,436
-24% -$7.24M 0.02% 817
2020
Q2
$33.1M Sell
430,343
-538,092
-56% -$41.2M 0.04% 529
2020
Q1
$72.4M Sell
968,435
-3,881,635
-80% -$268M 0.11% 199
2019
Q4
$315M Sell
4,850,070
-671,287
-12% -$43.7M 0.36% 36
2019
Q3
$350M Sell
5,521,357
-662,256
-11% -$43.3M 0.43% 26
2019
Q2
$418M Sell
6,183,613
-218,887
-3% -$14.4M 0.52% 20
2019
Q1
$416M Buy
6,402,500
+4,014,025
+168% +$267M 0.54% 21
2018
Q4
$149M Buy
2,388,475
+398,815
+20% +$27.9M 0.21% 97
2018
Q3
$154M Buy
1,989,660
+759,460
+62% +$57.4M 0.18% 111
2018
Q2
$87.1M Sell
1,230,200
-341,546
-22% -$24.1M 0.11% 209
2018
Q1
$118M Sell
1,571,746
-114,887
-7% -$9.13M 0.16% 149
2017
Q4
$121M Sell
1,686,633
-1,043,704
-38% -$79.3M 0.17% 144
2017
Q3
$221M Sell
2,730,337
-4,650,759
-63% -$356M 0.34% 50
2017
Q2
$522M Buy
7,381,096
+997,408
+16% +$66.4M 0.86% 5
2017
Q1
$434M Buy
6,383,688
+1,754,565
+38% +$123M 0.76% 9
2016
Q4
$331M Buy
4,629,123
+3,408,774
+279% +$253M 0.56% 16
2016
Q3
$96.6M Sell
1,220,349
-279,549
-19% -$22.7M 0.17% 129
2016
Q2
$125M Buy
1,499,898
+951,075
+173% +$84.4M 0.23% 92
2016
Q1
$50.4M Sell
548,823
-3,967,623
-88% -$358M 0.09% 258
2015
Q4
$457M Sell
4,516,446
-1,634,589
-27% -$170M 0.68% 11
2015
Q3
$604M Buy
6,151,035
+1,759,029
+40% +$195M 0.89% 7
2015
Q2
$514M Buy
4,392,006
+3,751,020
+585% +$410M 0.77% 10
2015
Q1
$62.9M Sell
640,986
-1,384,903
-68% -$141M 0.1% 238
2014
Q4
$191M Sell
2,025,889
-1,563,215
-44% -$162M 0.25% 71
2014
Q3
$382M Buy
3,589,104
+2,273,925
+173% +$223M 0.49% 24
2014
Q2
$109M Buy
1,315,179
+630,287
+92% +$49.1M 0.15% 140
2014
Q1
$48.5M Buy
684,892
+229,569
+50% +$18M 0.07% 308
2013
Q4
$34.2M Buy
455,323
+78,774
+21% +$5.49M 0.05% 439
2013
Q3
$23.7M Sell
376,549
-210,019
-36% -$12.6M 0.04% 514
2013
Q2
$30M Buy
+586,568
New +$30.6M 0.06% 374

Other funds holding GILD

D.E. Shaw & Co's GILD Position: Q1 2026 in Review

D.E. Shaw & Co increased its Gilead Sciences (GILD) stake by 4.3% in Q1 2026, buying an estimated $1.15M and bringing the position to 200,919 shares worth $28M. The position accounts for 0.02% of the portfolio, ranked #945.

D.E. Shaw & Co first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $604M in Q3 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • D.E. Shaw & Co held 200,919 shares of Gilead Sciences worth $28M as of Q1 2026.
  • D.E. Shaw & Co bought 8,214 Gilead Sciences shares in Q1 2026, an estimated $1.15M.
  • Gilead Sciences made up 0.02% of D.E. Shaw & Co's portfolio in Q1 2026, its #945 holding.
  • D.E. Shaw & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
  • D.E. Shaw & Co's Gilead Sciences position peaked at $604M in Q3 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.